1312 — Kontafarma China Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Kontafarma China Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,009	803	894	809	898
Cost of Revenue
Gross Profit	556	396	506	471	516
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	978	824	989	838	982
Operating Profit	31.1	-20.9	-94.5	-28.7	-84.6
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-0.297	-54.5	-118	-43.9	-98
Provision for Income Taxes
Net Income After Taxes	-20.1	-56.3	-110	-61.1	-99
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-267	-15	-41.5	-28.8	-75.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-267	-15	-41.5	-28.8	-75.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0	-0.007	-0.016	-0.018	-0.011